Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Part of paid clinical trials in Corona, California.

Sponsor
Exelixis
Study ID
NCT01908426
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.

Key Dates

Start date
Sep 26, 2013
Status verified
Apr 2021
Primary completion
Oct 16, 2017
Completion
Jan 12, 2021

Study Design

Enrollment
707 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cabozantinib (XL184)
    Cabozantinib (XL184) 60 mg tablet once daily
  • Placebo Comparator: Placebo
    Oral cabozantinib-matched placebo tablet once daily

Primary Outcome Measure

Overall Survival (OS) [ Time Frame: Up to 45 months ]

Locations (22)

FacilityCityStateZIPSite coordinators
-CoronaCalifornia92879-
-Los AngelesCalifornia90033-
-San DiegoCalifornia92123-
-San FranciscoCalifornia94115-
-GainesvilleFlorida32610-
-AtlantaGeorgia30318-
-HonoluluHawaii96815-
-ChicagoIllinois60637-
-BurlingtonMassachusetts01805-
-RochesterMinnesota55905-
-Kansas CityMissouri64128-
-St LouisMissouri63110-
-Las VegasNevada89109-
-East OrangeNew Jersey07018-
-New YorkNew York10032-
-New YorkNew York10065-
-ValhallaNew York10595-
-DallasTexas75246-
-San AntonioTexas78215-
-SeattleWashington98104-
-SeattleWashington98109-
-SpokaneWashington99208-

Find similar trials in Corona, CA

By condition
Liver cancer
By specialty
OncologyGI oncologyHepatology

Related Studies